Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM2000 Smallpox Vaccine Dose-Response Study
NCT00053495Phase 2Completed
- Sponsor
- Emergent BioSolutions
- Start
- Jan 2003
- Primary completion
- Jun 2003
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of smallpox (vaccinia) vaccine, live in smallpox, sponsored by Emergent BioSolutions. Started Jan 2003; status: completed.
02
Drugs
smallpox (vaccinia) vaccine, live
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00053495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053495.